Scholars@Duke
Michael Roger Harrison

Michael Roger Harrison

Associate Professor of Medicine
Medicine, Medical Oncology

Selected Publications

Design and Rationale of the Outcomes Database to Prospectively Assess the Changing Therapy Landscape in Renal Cell Carcinoma Registry: A Multi-institutional, Prospective Study of Patients with Metastatic Renal Cell Carcinoma.

Journal Article Eur Urol Open Sci · August 2024 INTRODUCTION AND HYPOTHESES: The Outcomes Database to prospectivelY aSSEss the changing TherapY landscape in Renal Cell Carcinoma (ODYSSEY RCC) Registry is a large, nationally representative prospective registry of patients with metastatic renal cell carci ... Full text Link to item Cite

Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer.

Journal Article Nat Commun · May 24, 2024 Neoadjuvant cisplatin-based chemotherapy is standard of care for muscle-invasive bladder cancer (MIBC). Immune checkpoint inhibition (ICI) alone, and ICI in combination with chemotherapy, have demonstrated promising pathologic response ( Full text Link to item Cite

Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer.

Journal Article Eur Urol · March 2024 BACKGROUND: Platinum-based neoadjuvant chemotherapy (NAC) is standard for patients with muscle-invasive bladder cancer (MIBC). Pathologic response (complete: ypT0N0 and partial: Full text Link to item Cite

Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer.

Journal Article Prostate Cancer Prostatic Dis · February 22, 2024 Combined androgen deprivation therapy (ADT) and radiotherapy (RT) improves outcomes for intermediate and high-risk prostate cancer. Treatment intensification with abiraterone acetate/prednisone (AAP) provides additional benefit for high-risk disease. We pr ... Full text Link to item Cite

Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors.

Journal Article J Natl Cancer Inst · December 6, 2023 BACKGROUND: Treatment options for penile squamous cell carcinoma are limited. We sought to investigate clinical outcomes and safety profiles of patients with penile squamous cell carcinoma receiving immune checkpoint inhibitors. METHODS: This retrospective ... Full text Link to item Cite

Relationship Between Pretreatment Body Composition and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Ipilimumab Plus Nivolumab.

Journal Article Clin Genitourin Cancer · December 2023 INTRODUCTION: Biomarkers are needed to identify patients with metastatic renal cell carcinoma (mRCC) most likely to benefit from immune checkpoint inhibitors. We examined associations between radiographically assessed body composition (BC) variables and bo ... Full text Link to item Cite

Assessing the utility of molecular diagnostic classification for cancers of unknown primary.

Journal Article Cancer Med · October 2023 BACKGROUND: Roughly 5% of metastatic cancers present with uncertain origin, for which molecular classification could influence subsequent management; however, prior studies of molecular diagnostic classifiers have reported mixed results with regard to clin ... Full text Link to item Cite

Feasibility of home-based exercise training in men with metastatic castration-resistant prostate cancer.

Journal Article Prostate Cancer Prostatic Dis · June 2023 BACKGROUND: Home-based training increases accessibility to exercise and mitigates the side effects of hormone therapy for prostate cancer (PC). However, it is unknown if men with more advanced disease are willing to partake in such interventions. PURPOSE: ... Full text Link to item Cite

Patient Preferences for Adjuvant Treatment in Muscle-Invasive Urothelial Carcinoma: A Multi-Country Discrete Choice Experiment.

Journal Article Patient Prefer Adherence · 2023 PURPOSE: The evolving treatment landscape in muscle-invasive urothelial carcinoma creates challenges for clinicians and patients in selecting the most appropriate therapy. Here, we aimed to understand adjuvant treatment preferences among patients with musc ... Full text Link to item Cite

The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma.

Journal Article Cancers · August 2022 A lower baseline neutrophil-to-eosinophil ratio (NER) has been associated with improved responses to immune checkpoint inhibitors (ICI)-treated metastatic renal cell carcinoma (mRCC). This study investigated the decrease in NER at week 6 after ipilimumab/n ... Full text Cite

Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer.

Journal Article Prostate · May 2022 BACKGROUND: In preclinical models of prostate cancer (PC), disulfiram (DSF) reduced tumor growth only when co-administered with copper (Cu), and Cu uptake in tumors is partially regulated by androgen-receptor signaling. However, prior trials of DSF in PC u ... Full text Link to item Cite

A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer.

Journal Article Prostate Cancer Prostatic Dis · April 2022 BACKGROUND: Men with progressive neuroendocrine or aggressive-variant metastatic prostate cancer (NEPC/AVPC) have a poor prognosis and limited treatment options, and immunotherapy has not been tested in such patients. METHODS: We conducted an open label si ... Full text Link to item Cite

A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND).

Journal Article Prostate Cancer Prostatic Dis · March 2022 BACKGROUND: Androgen deprivation therapy (ADT) and androgen receptor signaling inhibitors (ARSI) are associated with deleterious physical effects, which exercise may mitigate; however, exercise has never been studied in patients initiating treatment with A ... Full text Link to item Cite

Effect of neoadjuvant chemotherapy (NAC) on patient preferences for adjuvant treatment in muscle-invasive urothelial carcinoma (MIUC): A multi-country discrete choice experiment (DCE).

Conference Journal of Clinical Oncology · February 20, 2022 454 Background: Patient preference is an important factor in selecting appropriate treatment choices. Although underutilized, the standard of care for MIUC is with NAC, whereas evidence for adjuvant therapy is less clear. With th ... Full text Cite

A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience.

Journal Article Clin Genitourin Cancer · February 2022 INTRODUCTION: The Metastatic Renal Cell Carcinoma (MaRCC) Registry provides prospective data on real-world treatment patterns and outcomes in patients with metastatic renal cell carcinoma (mRCC). METHODS AND MATERIALS: Patients with mRCC and no prior syste ... Full text Link to item Cite

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.

Journal Article J Immunother Cancer · February 2022 BACKGROUND: CheckMate 920 (NCT02982954) is a multicohort, phase 3b/4 clinical trial of nivolumab plus ipilimumab treatment in predominantly US community-based patients with previously untreated advanced renal cell carcinoma (RCC) and clinical features most ... Full text Link to item Cite

Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial.

Journal Article Eur Urol Oncol · December 2021 BACKGROUND: Salvage external beam radiotherapy (RT) with androgen deprivation therapy (ADT) improves survival over RT in men with prostate cancer (PC) and rising prostate-specific antigen (PSA) levels after radical prostatectomy (RP). OBJECTIVE: To investi ... Full text Link to item Cite

Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma.

Journal Article JAMA oncology · December 2021 ImportancePatients with brain metastases from renal cell carcinoma (RCC) have been underrepresented in clinical trials, and effective systemic therapy is lacking. Cabozantinib shows robust clinical activity in metastatic RCC, but its effect on bra ... Full text Cite

Referral and adjuvant treatment patterns after nephrectomy in high-risk locoregional renal cell carcinoma.

Journal Article Cancer Med · December 2021 BACKGROUND: It is unclear whether patients with renal cell carcinoma (RCC) are routinely assessed for recurrence risk post-nephrectomy and whether patients at high recurrence risk are seen by providers who can evaluate candidacy for adjuvant systemic thera ... Full text Link to item Cite

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.

Journal Article Eur Urol Open Sci · December 2021 BACKGROUND: Phase 2 trial endpoints that can be utilized in high-risk biochemical recurrence (BCR) after prostatectomy as a way of more rapidly identifying treatments for phase 3 trials are urgently needed. The efficacy of abiraterone acetate plus predniso ... Full text Link to item Cite

Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma.

Journal Article Biomark Res · November 3, 2021 BACKGROUND: The identification of biomarkers to select patients with metastatic renal cell carcinoma (mRCC) most likely to respond to combination immunotherapy (IO) is needed. We sought to investigate an association of the baseline neutrophil-to-eosinophil ... Full text Link to item Cite

Five Year Results of Short Course Complete Androgen Blockade With Abiraterone Acetate and LHRH Agonist for Unfavorable Intermediate and Favorable High Risk Prostate Cancer.

Conference International journal of radiation oncology, biology, physics · November 2021 Purpose/objective(s)Androgen deprivation therapy (ADT) and radiotherapy (RT) are synergistic, and the combination results in improved survival outcomes for aggressive prostate cancers. However, long-term ADT carries substantial burden of toxicity ... Full text Cite

Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.

Journal Article J Clin Oncol · October 1, 2021 PURPOSE: To evaluate the safety and efficacy of gemcitabine and cisplatin in combination with the immune checkpoint inhibitor pembrolizumab as neoadjuvant therapy before radical cystectomy (RC) in muscle-invasive bladder cancer. METHODS: Patients with clin ... Full text Link to item Cite

Body composition, physical function and quality of life in healthy men and across different stages of prostate cancer.

Journal Article Prostate Cancer Prostatic Dis · September 2021 BACKGROUND: Androgen deprivation therapy (ADT) for prostate cancer (PC) has detrimental effects on physical function and quality of life (QoL), but the addition of androgen receptor signalling inhibitors (ARSI) on these outcomes is unclear. PURPOSE: To com ... Full text Link to item Cite

A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.

Journal Article Cancer · August 15, 2021 BACKGROUND: Retrospective analyses of randomized trials suggest that Black men with metastatic castration-resistant prostate cancer (mCRPC) have longer survival than White men. The authors conducted a prospective study of abiraterone acetate plus prednison ... Full text Link to item Cite

Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC).

Journal Article Cancer · July 1, 2021 BACKGROUND: Systemic therapy (ST) can be deferred in patients who have metastatic renal cell carcinoma (mRCC) and slow-growing metastases. Currently, this subset of patients managed with active surveillance (AS) is not well described in the literature. MET ... Full text Open Access Link to item Cite

Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.

Journal Article The Lancet. Oncology · June 2021 BackgroundLocally advanced or metastatic urothelial carcinoma is generally incurable and has scarce treatment options, especially for cisplatin-ineligible patients previously treated with PD-1 or PD-L1 therapy. Enfortumab vedotin is an antibody-dr ... Full text Cite

Association of baseline neutrophil-to-eosinophil ratio (NER) and neutrophil-to-lymphocyte ratio (NLR) with response to combination immunotherapy (IO) with ipilimumab plus nivolumab (ipi/nivo) in patients with metastatic renal cell carcinoma (mRCC).

Conference Journal of Clinical Oncology · May 20, 2021 4563 Background: Previous reports have shown that the baseline neutrophil-to-lymphocyte ratio (NLR) is associated with prognosis in patients with mRCC. However, NLR has not been shown to reliably predict for response to IO. Retro ... Full text Cite

Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort 2.

Conference Journal of Clinical Oncology · May 20, 2021 4524 Background: Cisplatin (cis)-ineligible, platinum-naive patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) who progress on/after anti-PD-1/L1 treatment (tx) have a poor prognosis and few tx optio ... Full text Cite

Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer.

Journal Article Int J Radiat Oncol Biol Phys · April 1, 2021 PURPOSE: Long-term androgen-deprivation therapy (ADT) is the standard of care in combination with radiation therapy (RT) in high-risk prostate cancer (PC), despite substantial toxicity from the resulting hypogonadism. We hypothesized that a combination of ... Full text Link to item Cite

Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.

Journal Article Cancer Med · April 2021 INTRODUCTION: Two separate antiangiogenic tyrosine kinase inhibitors (TKIs) and immunotherapy (IO) combinations are FDA-approved as front-line treatment for metastatic renal cell carcinoma (mRCC). Little is known about off-protocol and post-front-line expe ... Full text Link to item Cite

Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma diagnosed between 2008 and 2012.

Journal Article J Geriatr Oncol · March 2021 PURPOSE: Treatment of advanced urothelial carcinoma (UC) remains a challenging clinical entity occurring predominantly in older patients with limited treatment options. However, real-world treatment patterns, differential cancer center access, and associat ... Full text Link to item Cite

LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types.

Journal Article J Immunother Cancer · March 2021 BACKGROUND: Low-density lipoprotein receptor-related protein 1b (encoded by LRP1B) is a putative tumor suppressor, and preliminary evidence suggests LRP1B-mutated cancers may have improved outcomes with immune checkpoint inhibitors (ICI). METHODS: We condu ... Full text Open Access Link to item Cite

Interim analysis of STARTAR: A phase II salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).

Conference Journal of Clinical Oncology · February 20, 2021 90 Background: ADT with salvage RT improves survival for men with PSA recurrence after RP. Current standard duration of ADT for high risk PSA recurrence is up to 2 years with RT; therefore shortening but intensifying systemic the ... Full text Cite

Nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC): Safety and efficacy from CheckMate 920.

Conference Journal of Clinical Oncology · February 20, 2021 309 Background: The long-term efficacy and tolerability of nivolumab (NIVO) 3 mg/kg + ipilimumab (IPI) 1 mg/kg Q3W × 4 doses followed by NIVO 3 mg/kg Q2W for previously untreated advanced RCC (aRCC) demonstrated in the registrati ... Full text Cite

ASSET: Alternative schedule sunitinib in metastatic renal cell carcinoma (RCC)—Cardiopulmonary exercise testing (CPET).

Conference Journal of Clinical Oncology · February 20, 2021 300 Background: Sunitinib (SUN) is a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) approved for treatment of advanced RCC and high risk RCC after nephrectomy. Evidence suggests that a 2 week (wk) on, 1 ... Full text Cite

Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy prior to radical cystectomy (RC) in patients with muscle-invasive bladder cancer (MIBC).

Conference Journal of Clinical Oncology · February 20, 2021 396 Background: Cisplatin-based neoadjuvant chemotherapy is standard of care in MIBC with improved pathologic response and overall survival (OS) compared to RC alone. Pembrolizumab (pembro) is active in high-risk non-muscle invas ... Full text Cite

Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and low Karnofsky performance status: Results from the CheckMate 920 trial.

Conference Journal of Clinical Oncology · February 20, 2021 315 Background: Combination therapy with nivolumab + ipilimumab (NIVO+IPI) has demonstrated long-term efficacy and tolerability for patients (pts) with previously untreated advanced renal cell carcinoma (aRCC). Most pivotal clini ... Full text Cite

Efficacy of the PD-L1 inhibitor avelumab in neuroendocrine or aggressive variant prostate cancer: Results from a phase II, single-arm study.

Conference Journal of Clinical Oncology · February 20, 2021 89 Background: Men with metastatic neuroendocrine/small cell and aggressive variant prostate cancer (NEPC/AVPC) have poor outcomes despite platinum and taxane chemotherapy. These tumors share common features with small cell lung ... Full text Cite

EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.

Conference Journal of Clinical Oncology · February 20, 2021 394 Background: Cisplatin (cis)-ineligible, platinum-naive patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) who progress on/after PD-1/L1 inhibitors (PD-1/L1-i) have a poor prognosis and few treatm ... Full text Cite

Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.

Journal Article Clinical cancer research : an official journal of the American Association for Cancer Research · January 2021 PurposePatients with advanced renal cell carcinoma with sarcomatoid features (sRCC) have poor prognoses and suboptimal outcomes with targeted therapy. This post hoc analysis of the phase III CheckMate 214 trial analyzed the efficacy of nivo ... Full text Cite

PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma.

Journal Article Clin Genitourin Cancer · December 2020 BACKGROUND: Immune checkpoint inhibitors are now standard of care for many patients with metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC). Given real-world limitations in programmed death-ligand 1 (PD-L1) testing, concordanc ... Full text Link to item Cite

Novel therapies are changing treatment paradigms in metastatic prostate cancer.

Journal Article J Hematol Oncol · October 28, 2020 Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with an aggressive disease course despite currently approved therapeutics. The recent successful development of poly ADP-ribose polymerase (PARP) inhibitors for patients w ... Full text Link to item Cite

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.

Journal Article Cancer · October 15, 2020 BACKGROUND: Inhibition of the programmed cell death protein 1 (PD-1) pathway has demonstrated clinical benefit in metastatic urothelial cancer (mUC); however, response rates of 15% to 26% highlight the need for more effective therapies. Bruton tyrosine kin ... Full text Open Access Link to item Cite

Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer.

Journal Article J Oncol Pharm Pract · March 2020 BACKGROUND: Neoadjuvant cisplatin-based combination chemotherapy for muscle-invasive bladder cancer (MIBC) improves overall and disease-free survival. However, there is much debate over the optimal neoadjuvant regimen. Gemcitabine plus cisplatin (GC) has b ... Full text Open Access Link to item Cite

Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group.

Journal Article Urol Oncol · March 2020 Survivorship care for patients with prostate cancer requires careful consideration of unique disease-specific factors, including the prolonged natural disease history, the potential for competing health risks, and the consequences of long-term androgen dep ... Full text Link to item Cite

Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study.

Journal Article J Immunother Cancer · March 2020 BACKGROUND: There is limited experience regarding the safety and efficacy of checkpoint inhibitors (CPI) in patients with autoimmune disorders (AD) and advanced urological cancers as they are generally excluded from clinical trials due to risk of exacerbat ... Full text Link to item Cite

Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer.

Journal Article JCO Precis Oncol · 2020 PURPOSE: Androgen receptor splice variant 7 (AR-V7) detection in circulating tumor cells (CTCs) is associated with a low probability of response and short progression-free (PFS) and overall survival (OS) in men with metastatic castration-resistant prostate ... Full text Link to item Cite

Metastatic Urothelial Carcinoma from Transplanted Kidney with Complete Response to an Immune Checkpoint Inhibitor.

Journal Article Case Rep Urol · 2020 BACKGROUND: Donor-derived malignancy is a rare complication in patients who undergo organ transplant. Approaches to treatment have largely been individualized based on clinical circumstances given the lack of evidence-based guidelines, with therapeutic opt ... Full text Open Access Link to item Cite

Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients.

Journal Article Prostate Cancer Prostatic Dis · December 2019 BACKGROUND: Sipuleucel-T is an autologous cellular immunotherapy that is FDA approved for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (mCRPC). The IMPACT registry trial demonstrated a 4.1 month survi ... Full text Link to item Cite

Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.

Journal Article Prostate · November 2019 BACKGROUND: Docetaxel prednisone is a standard of care for men with metastatic castration-resistant prostate cancer (mCRPC), and plasma vascular endothelial growth factor (VEGF) levels are a poor prognostic factor in this population; therefore, we evaluate ... Full text Link to item Cite

NCCN Guidelines Insights: Kidney Cancer, Version 2.2020.

Journal Article Journal of the National Comprehensive Cancer Network : JNCCN · November 2019 The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal cell carcinoma, and are intended to assist with clinical decision-making. These NCCN Guidelines ... Full text Cite

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.

Journal Article The Lancet. Oncology · October 2019 BackgroundIn the ongoing phase 3 CheckMate 214 trial, nivolumab plus ipilimumab showed superior efficacy over sunitinib in patients with previously untreated intermediate-risk or poor-risk advanced renal cell carcinoma, with a manageable safety pr ... Full text Cite

Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer.

Journal Article Cancer Med · August 2019 BACKGROUND: Pembrolizumab is approved for patients with metastatic, microsatellite instability (MSI)-high or mismatch repair-deficient (dMMR) solid tumors. However, very few men with prostate cancer were included in these initial studies. METHODS: We perfo ... Full text Link to item Cite

Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.

Journal Article Clin Genitourin Cancer · June 2019 The incidence of renal-cell carcinoma has been increasing each year, with nearly one third of new cases diagnosed at advanced or metastatic stage. The advent of targeted therapies for metastatic renal-cell carcinoma (mRCC) has underscored the need to subty ... Full text Link to item Cite

A phase II Salvage Trial of AR Inhibition with ADT and Apalutamide with Radiation therapy followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (STARTAR).

Conference Journal of Clinical Oncology · May 20, 2019 TPS5097 Background: Androgen deprivation combined with salvage external beam radiation therapy (RT) have improved survival for patients (pts) with non-metastatic hormone naïve PC and PSA recurrence after radical prostatectomy (RP ... Full text Cite

Immune checkpoint inhibitor response in tumors with LRP1B variants.

Conference Journal of Clinical Oncology · May 20, 2019 e14291 Background: Low-density lipoprotein receptor-related protein 1B (LRP1B) is a putative tumor suppressor gene spanning > 500 kb on chromosome 2. A melanoma study previously reported enrichment of LRP1B mutations in respon ... Full text Cite

Prevalence of pathogenic germline variants in DNA repair by race, age, and ethnicity in men with prostate cancer.

Conference Journal of Clinical Oncology · May 20, 2019 5062 Background: Patients with advanced prostate cancer (PC) frequently harbor pathogenic or likely pathogenic (P/LP) germline variants (GVs) in mismatch repair (MMR) and homologous repair (HR) enzymes which have clinical and tre ... Full text Cite

Evaluation of the patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) with abiraterone acetate plus prednisone (AAP), degarelix (D), or the combination in men with biochemically recurrent prostate cancer (BCRPC).

Conference Journal of Clinical Oncology · May 20, 2019 5080 Background: Patient-reported symptoms using the PRO-CTCAE provide insights into the patient experience with care. Earlier use of AAP (an androgen biosynthesis inhibitor plus prednisone) with androgen deprivation therapy in c ... Full text Cite

CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features.

Conference Journal of Clinical Oncology · May 20, 2019 4513 Background: Patients (pts) with advanced renal cell carcinoma with sarcomatoid features (sRCC) have poor prognosis and suboptimal outcomes with anti-VEGF targeted therapy. Nivolumab plus ipilimumab (N+I) demonstrated superio ... Full text Cite

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.

Journal Article The Lancet. Oncology · April 2019 BackgroundCabozantinib is approved for patients with metastatic renal cell carcinoma on the basis of studies done in clear-cell histology. The activity of cabozantinib in patients with non-clear-cell renal cell carcinoma is poorly characterised. W ... Full text Cite

Magnetic compression anastomosis (magnamosis) in a porcine esophagus: Proof of concept for potential application in esophageal atresia.

Journal Article J Pediatr Surg · March 2019 BACKGROUND: Magnetic compression anastomosis (magnamosis) is the process of forming a sutureless anastomosis of the gastrointestinal tract using two magnetic Harrison rings. It has been shown to be effective in stomach, small bowel and colon, but has not b ... Full text Link to item Cite

Multidimensional flow characterization of circulating immune cells in cisplatin-resistant metastatic urothelial cancer (mUC) patients (pts) treated with pembrolizumab (P) with or without acalabrutinib (acala).

Conference Journal of Clinical Oncology · March 1, 2019 357 Background: Immunotherapy checkpoint inhibitors (ICIs) are now standard treatments (txs) in mUC, with response rates ranging 15-25%. A phase 2 randomized study (NCT02351739) treated 75 pts with mUC with either P or PA. We pro ... Full text Cite

Pembrolizumab in men with heavily treated metastatic castration-resistant prostate cancer (mCRPC).

Conference Journal of Clinical Oncology · March 1, 2019 172 Background: Pembrolizumab is approved for patients with metastatic, microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors who have progressed on prior therapy and have no satisfactory treatm ... Full text Cite

PEAX: Men with metastatic castrate-resistant prostate cancer (mCRPC) treated with either sipuleucel-T (SIP-T), enzalutamide (ENZA) or abiraterone acetate (ABI) undergoing cardiopulmonary exercise testing (CPET).

Conference Journal of Clinical Oncology · March 1, 2019 281 Background: Both ENZA and ABI are associated with significant toxicity to the cardiovascular-musculoskeletal system and physical side effects. However whether they cause a decline in cardiorespiratory fitness (CRF), as conven ... Full text Cite

Phase II trial enzalutamide and androgen deprivation therapy (ADT) with salvage radiation in men with high-risk PSA recurrent prostate cancer (PC): The STREAM trial.

Conference Journal of Clinical Oncology · March 1, 2019 29 Background: Salvage external beam radiotherapy (RT) and hormonal therapy improves survival over RT alone in men with non-metastatic hormone naïve PC and PSA recurrence after radical prostatectomy (RP). We investigated the safe ... Full text Cite

Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214.

Conference Journal of Clinical Oncology · March 1, 2019 564 Background: TFS characterizes the antitumor activity of immuno-oncology agents after treatment discontinuation. In CheckMate 214, pts with IMDC intermediate/poor-risk aRCC who discontinued first-line NIVO+IPI experienced sign ... Full text Cite

Real-World Data from a Metastatic Renal Cell Carcinoma Community-Academic Registry: Comparative Outcomes of Progression Free Survival and Overall Survival

Journal Article Kidney Cancer · January 1, 2019 Background: No studies have looked at comparative outcomes in the treatment of metastatic renal cell carcinoma (mRCC) between academic and community practice settings. Methods: We created a joint academic (ACAD) and community (COMM) retrospective registry ... Full text Cite

Cancer of the Kidney

Chapter · January 1, 2019 Renal cell carcinoma (RCC) accounts for approximately 4% of adult malignancies, including approximately 90% of primary renal tumors. RCC exists in sporadic and hereditary forms and is a clinically and pathologically heterogeneous disease. The WHO classific ... Full text Cite

Urologic Malignancies

Chapter · January 1, 2019 Immune checkpoint inhibitors (ICI) have revolutionized the care of urologic malignancies, in particular urothelial carcinoma (UC) and renal cell carcinoma (RCC). Five PD-1/PD-L1 ICIs have been approved for platinum-refractory advanced UC: atezolizumab, pem ... Full text Cite

Androgen deprivation therapy (ADT) and cardiovascular mortality (CVD) in men with early-stage prostate cancer (PC) receiving curative radiation therapy (RT).

Conference Journal of Clinical Oncology · March 1, 2018 127 Background: Combined with RT, ADT is a highly effective and utilized treatment for men with localized PC, but some studies suggest that use of ADT leads to increased CVD. We explored the association between ADT and CVD in men ... Full text Cite

Phase II trial of 6 months ADT/abiraterone acetate plus prednisone (AAP) and definitive radiotherapy (AbiRT) for men with intermediate to high risk localized prostate cancer.

Conference Journal of Clinical Oncology · February 20, 2018 11 Background: Combined external beam radiotherapy (RT) and androgen deprivation therapy (ADT) improves survival over RT alone for high risk prostate cancer (PC). Long-term ADT use, currently recommended for high risk PC, also in ... Full text Cite

Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract: an evidence-based review of safety, efficacy, and place in therapy.

Journal Article Core Evid · 2018 BACKGROUND: A systematic review and meta-analysis of the use of systemic vinflunine (VIN) in the treatment of urothelial carcinoma (UC) was performed to evaluate its efficacy based on current available clinical data. METHODS: This review was prospectively ... Full text Link to item Cite

Physical activity patterns and associations with health-related quality of life in bladder cancer survivors.

Journal Article Urol Oncol · September 2017 INTRODUCTION: Physical activity has been shown to significantly improve health-related quality of life (HRQOL) and survivorship in a variety of patients with cancer . However, little is known about the physical activity patterns of bladder cancer survivors ... Full text Link to item Cite

Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer.

Journal Article Urol Oncol · June 2017 PURPOSE: Evidence suggests differences in androgen receptor AR signaling between black (B) and white (W) patients with prostate cancer, but pivotal trials of abiraterone acetate (AA) for patients with metastatic castration-resistant prostate cancer (mCRPC) ... Full text Link to item Cite

Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Journal Article J Natl Compr Canc Netw · June 2017 The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal carcinoma. These guidelines are developed by a multidisciplinary panel of leading experts from ... Full text Link to item Cite

Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer.

Journal Article Cancer Invest · May 28, 2017 The Metastatic Renal Cell Cancer Registry, a large, nationally representative, prospective registry of patients with metastatic renal cell carcinoma (mRCC), aims to understand real-world treatment patterns and outcomes of patients with mRCC in routine clin ... Full text Link to item Cite

Association of neuroendocrine phenotype with platinum chemotherapy outcomes in men with metastatic prostate cancer.

Conference Journal of Clinical Oncology · May 20, 2017 e16532 Background: DNA repair defects are common in men with mCRPC, and platinum chemotherapy may have a role in selected patients. We aimed to determine whether neuroendocrine variant prostate cancer (NEPC) is associated with a ... Full text Cite

Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer.

Journal Article Clin Cancer Res · April 15, 2017 Atezolizumab (Tecentriq, MPDL3280A; Genentech/Roche) is an FcγR binding-deficient, fully humanized IgG1 mAb designed to interfere with the binding of PD-L1 ligand to its two receptors, PD-1 and B7.1. By blocking the PD-L1/PD-1 immune checkpoint, atezolizum ... Full text Link to item Cite

How Can We Effectively Address the Medical and Psychological Concerns of Survivors of Pelvic Malignancies?

Journal Article Oncology (Williston Park) · April 15, 2017 Sexual and urinary morbidities resulting from treatment of pelvic malignancies are common. These treatment sequelae are significantly bothersome to patients and challenging to address. Awareness of these complications is critical in order to properly couns ... Link to item Cite

Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.

Conference Prostate · March 2017 BACKGROUND: Tasquinimod is an immunomodulating and anti-antiangiogenic oral agent with anti-prostate cancer activity in preclinical studies and in clinical trials of men with metastatic castration resistant prostate cancer (mCRPC), including single agent a ... Full text Link to item Cite

Treatment-related neuroendocrine prostate cancer resulting in Cushing's syndrome.

Journal Article Int J Urol · December 2016 Here we present, to the best of our knowledge, the first case of a paraneoplastic Cushing's syndrome (hypercortisolism) resulting from treatment-related neuroendocrine prostate cancer - a highly aggressive and difficult disease to treat. A 51-year-old man ... Full text Link to item Cite

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.

Journal Article Clin Cancer Res · November 15, 2016 PURPOSE: Nivolumab, an anti-PD-1 immune checkpoint inhibitor, improved overall survival versus everolimus in a phase 3 trial of previously treated patients with metastatic renal cell carcinoma (mRCC). We investigated immunomodulatory activity of nivolumab ... Full text Link to item Cite

High rates of venous thromboembolic events in patients undergoing systemic therapy for urothelial carcinoma: A systematic review and meta-analysis.

Journal Article Urol Oncol · September 2016 BACKGROUND: Patients undergoing systemic therapy for urothelial carcinoma (UC) are at increased risk for venous thromboembolic (VTE) events. The objective of the current study was to determine the rate of VTE events in patients undergoing systemic therapy ... Full text Link to item Cite

Development of a Novel c-MET-Based CTC Detection Platform.

Journal Article Mol Cancer Res · June 2016 UNLABELLED: Amplification of the MET oncogene is associated with poor prognosis, metastatic dissemination, and drug resistance in many malignancies. We developed a method to capture and characterize circulating tumor cells (CTC) expressing c-MET using a fe ... Full text Open Access Link to item Cite

Resistance exercise training in patients with genitourinary cancers to mitigate treatment-related skeletal muscle loss.

Journal Article Clin Adv Hematol Oncol · June 2016 The use of targeted therapies in patients with genitourinary malignancies has significantly improved outcomes. For example, androgen receptor (AR) pathway inhibitors have improved outcomes for patients with prostate cancer, and antiangiogenic agents have i ... Link to item Cite

Phase Ib trial of docetaxel, prednisone, and pazopanib, in men with metastatic castration resistant prostate cancer (mCRPC).

Conference Journal of Clinical Oncology · January 10, 2016 275 Background: Docetaxel prednisone (DP) is a standard of care for men with metastatic castrate resistant prostate cancer (mCRPC) with median progression-free survival (PFS) of 4-6 months and overall survival (OS) of 19 months, ... Full text Cite

Physician treatment selection in the prospective Metastatic Renal Cell Cancer (MaRCC) Registry.

Conference Journal of Clinical Oncology · January 10, 2016 563 Background: Clinical trials mRCC pts are different from real world pts, resulting in bias in the literature. The MaRCC Registry is designed to survey questions not asked in tri als, such as why physicians make certain managem ... Full text Cite

Front-line management patterns in the prospective metastatic renal cell cancer (MaRCC) registry.

Conference Journal of Clinical Oncology · January 10, 2016 617 Background: Over the past decade, seven agents were approved for metastatic renal cell carcinoma (mRCC) leading to a rapidly evolving clinical landscape. Clinical trials addressing treatment efficacy, sequencing, and other qu ... Full text Cite

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Journal Article New England Journal of Medicine · November 5, 2015 Full text Cite

Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice.

Journal Article J Oncol Pract · November 2015 PURPOSE: Although narrow eligibility criteria improve the internal validity of clinical trials, they may result in differences between study populations and real-world patients, threatening generalizability. Therefore, we evaluated whether patients treated ... Full text Link to item Cite

What Should We Tell Patients About Physical Activity After a Prostate Cancer Diagnosis?

Journal Article Oncology (Williston Park) · September 2015 A number of observational studies and clinical trials have shown that physical activity after a diagnosis of prostate cancer is associated with a decrease in disease progression and an increase in survival, and that specific exercises reduce morbidity from ... Link to item Cite

Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.

Journal Article Clin Genitourin Cancer · August 2015 BACKGROUND: Abiraterone acetate (AA) has demonstrated improved outcomes in men with metastatic castration-resistant prostate cancer (mCRPC). However, data are lacking on the effect of AA on subsequent efficacy of enzalutamide or docetaxel. PATIENTS AND MET ... Full text Link to item Cite

Deferred systemic therapy in patients with metastatic renal cell carcinoma.

Journal Article Clin Genitourin Cancer · June 2015 BACKGROUND: With the advent of small-molecule "targeted" therapies, the prevailing treatment paradigm for metastatic renal cell carcinoma (mRCC) is that all patients who are able to tolerate systemic therapy should receive it. However, oncologists often de ... Full text Link to item Cite

Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer.

Journal Article Prostate Cancer Prostatic Dis · June 2015 BACKGROUND: Owing to efficacy and tolerability, abiraterone acetate (AA) is a leading treatment for men with metastatic castration-resistant prostate cancer. Increased serum concentrations of AA, such as by taking AA with food, may lead to the inhibition o ... Full text Link to item Cite

Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution.

Journal Article Clin J Oncol Nurs · June 2015 BACKGROUND: Sipuleucel-T, an autologous cellular immunotherapy, is approved for the treatment of certain patients with metastatic castration-resistant prostate cancer (mCRPC). Sipuleucel-T is the first personalized treatment for prostate cancer to be manuf ... Full text Link to item Cite

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.

Journal Article Journal of clinical oncology : official journal of the American Society of Clinical Oncology · May 2015 PurposeNivolumab is a fully human immunoglobulin G4 programmed death-1 immune checkpoint inhibitor antibody that restores T-cell immune activity. This phase II trial assessed the antitumor activity, dose-response relationship, and safety of nivolu ... Full text Cite

Use of "Real-World" data to describe adverse events during the treatment of metastatic renal cell carcinoma in routine clinical practice.

Journal Article Med Oncol · September 2014 Insights into the experience of metastatic renal cell carcinoma (mRCC) patients are needed to optimize patient care. A retrospective, multicenter registry of mRCC patients treated at academic (Duke) and community (ACORN) practices was developed to fill thi ... Full text Link to item Cite

Real-world outcomes in metastatic renal cell carcinoma: insights from a Joint Community-Academic Registry.

Journal Article J Oncol Pract · March 2014 INTRODUCTION: As new therapeutics for metastatic renal cell carcinoma (mRCC) are quickly introduced to market, comparative randomized trial evidence guiding treatment decisions is lacking, especially in the second treatment exposure and beyond. As a demons ... Full text Link to item Cite

Treatment selection in metastatic renal cell carcinoma: more confusion or a path forward?

Journal Article Clin Adv Hematol Oncol · March 2014 Meaningful progress has been realized in the treatment of metastatic renal cell carcinoma with the recent approval of a number of new agents; more new agents are on the horizon. Despite the recent completion of many clinical trials that have changed or wil ... Link to item Cite

"Real world" treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy.

Journal Article Clin Genitourin Cancer · December 2013 BACKGROUND: New targeted therapeutics approved for metastatic renal cell carcinoma (mRCC) offer multiple options in each line of therapy; however, there are few prospective data beyond the first-line settings, and overall comparative effectiveness data are ... Full text Link to item Cite

Novel immunotherapeutic strategies in development for renal cell carcinoma.

Journal Article Eur Urol · May 2013 CONTEXT: The purpose of this report is to review immunotherapies under investigation for patients with renal cell carcinoma (RCC), the most common form of kidney cancer, for which the incidence and mortality rate continue to increase. OBJECTIVE: To summari ... Full text Link to item Cite

A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.

Journal Article Cancer Chemother Pharmacol · April 2013 PURPOSE: KX2-391 is an oral non-ATP-competitive inhibitor of Src kinase and tubulin polymerization. In phase 1 trials, prostate-specific antigen (PSA) declines were seen in patients with advanced prostate cancer. We conducted a single-arm phase 2 study eva ... Full text Link to item Cite

Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.

Journal Article Clin Genitourin Cancer · March 2013 PURPOSE: The activity of systemic agents after progression when using vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibition (TKI) and mammalian target of rapamycin (mTOR) inhibition in patients with metastatic renal cell carcinoma ... Full text Link to item Cite

Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease.

Journal Article Cancer Manag Res · 2013 BACKGROUND: Radium-223 chloride ((223)Ra; Alpharadin) is an alpha-emitting radioisotope that targets areas of osteoblastic metastasis and is excreted by the small intestine. When compared with beta-emitters (eg, strontium-89, samarium-153), (223)Ra deliver ... Full text Link to item Cite

Activity of single-agent bevacizumab (B) in patients with metastatic renal cell carcinoma (RCC) previously treated with VEGF- and mTOR-based therapies.

Journal Article J Clin Oncol · February 10, 2012 435 Background: Given a lack of clinical information on therapeutic efficacy of agents following progression after vascular endothelial growth factor (VEGF) tyrosine kinase inhibition (TKI) and mammalian target of rapamycin (mTOR) inhibition in metastatic ... Full text Link to item Cite

Outcomes of “real world” treatment for metastatic renal cell carcinoma (mRCC).

Journal Article Journal of Clinical Oncology · February 10, 2012 406 Background: Targeted therapies have expanded treatment options for mRCC. Using a joint community/academic center database, we determined outcomes for “real world” mRCC patients (pts) in order to understand current treatment p ... Full text Cite

Outcomes of "real world" treatment for metastatic renal cell carcinoma (mRCC).

Journal Article J Clin Oncol · February 10, 2012 406 Background: Targeted therapies have expanded treatment options for mRCC. Using a joint community/academic center database, we determined outcomes for "real world" mRCC patients (pts) in order to understand current treatment patterns and their effective ... Link to item Cite

Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate.

Journal Article Clin Cancer Res · December 15, 2011 PURPOSE: To characterize proliferative changes in tumors during the sunitinib malate exposure/withdrawal using 3'-deoxy-3'-[(18)F]fluorothymidine (FLT) positron emission tomography (PET)/computed tomography (CT) imaging. PATIENTS AND METHODS: Patients with ... Full text Link to item Cite

Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) resistance in metastatic renal cell carcinoma (mRCC): Possible mechanisms and clinical approaches

Journal Article European journal of Clinical and Medical Oncology · December 1, 2011 Introduction: The approvals of sorafenib, sunitinib, and pazopanib have led to increased options for patients with mRCC. Unfortunately, some patients treated with these vascular endothelial growth factor receptor (VEGFR) TKI progress rapidly, while the maj ... Cite

A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC).

Journal Article Invest New Drugs · December 2011 PURPOSE: 2ME2 (Panzem®) is a non-estrogenic derivative of estradiol with antiproliferative and antiangiogenic activity. Preclinical data support antitumor activity in prostate cancer. This trial evaluated the efficacy of 2ME2 NCD in patients with taxane-re ... Full text Link to item Cite

Better late than early: FDG-PET imaging in metastatic renal cell carcinoma.

Journal Article Clin Cancer Res · September 15, 2011 Sunitinib treatment benefits patients with metastatic renal cell carcinoma (mRCC), but response duration can vary widely and resistance is not predicted by standard measures. [¹⁸F]fluoro-2-deoxy-2-D-glucose positron emission tomography (FDG-PET) uptake is ... Full text Link to item Cite

Pharmacotherapy options in advanced renal cell carcinoma: what role for pazopanib?

Journal Article Clin Med Insights Oncol · 2011 Over the last 6 years, the treatment of metastatic renal cell carcinoma (mRCC) has undergone dramatic changes. A better understanding of the pathogenesis and tumor biology of sporadic renal cell carcinoma has led to the approval of 6 drug regimens: 3 oral ... Full text Link to item Cite

Pazopanib for the treatment of patients with advanced renal cell carcinoma.

Journal Article Clin Med Insights Oncol · October 1, 2010 Dramatic advances in the care of patients with advanced renal cell carcinoma have occurred over the last ten years, including insights into the molecular pathogenesis of this disease, that have now been translated into paradigm-changing therapeutic strateg ... Full text Link to item Cite

Response to antiangiogenesis therapy in a patient with advanced adult-type testicular granulosa cell tumor.

Journal Article Oncology (Williston Park) · August 2009 As granulosa cell tumors of the adult type are extremely uncommon testicular neoplasms, relatively few case reports and case series have been published. Treatment for localized, small-volume, or oligometastatic disease is generally surgical resection alone ... Link to item Cite

Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins.

Journal Article Clin Adv Hematol Oncol · January 2009 Until recently, development of chemotherapeutic agents that target mitosis has centered on inhibiting the mitotic spindle through interactions with microtubules. The taxanes, while significantly advancing the treatment of many types of cancer, suffer from ... Link to item Cite

Distribution of proteasomes and of the five proteolytic activities in rat tissues.

Journal Article Arch Biochem Biophys · February 15, 2000 Five peptidase activities (ChT-L, T-L, PGPH, BrAAP, and SNAAP) of the proteasome, and its caseinolytic activity, were measured in crude extracts of 10 rat tissues under experimental conditions simulating those found in vivo, thereby eliminating the alterat ... Full text Link to item Cite

Changes in skeletal muscle cross sectional area (CSA) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZ).

Journal Article Journal of Clinical Oncology Background: Phase III studies that led to ENZ approval in the treatment of mCRPC included side effects like fatigue, musculoskeletal pain, and falls, which could result from skeletal muscle loss. Such muscle loss (sarcopenia), in a variety of cancer popula ... Full text Link to item Cite